For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Noriaki Ishida, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com
Daiichi Sankyo Launches Denotas® Chewable Combination Tablets with Calcium/Natural Vitamin D3/Magnesium
Tokyo, Japan (May 31, 2013) – Daiichi Sankyo Company, Limited today announced the launch in Japan of Denotas® chewable combination tablets with calcium, natural vitamin D3, magnesium (precipitated calcium carbonate/cholecalciferol (vitamin D3)/magnesium carbonate combination tablets).
Nitto Pharmaceutical Industries, Ltd. received approval on February 28, 2013 for the manufacturing and marketing of Denotas® for the treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab).
Product overview
Launch date: May 31, 2013
|
Product name
|
DENOTASⓇ CHEWABLE COMBINATION TABLETS
|
|
Agent
|
Calcium, natural vitamin D3, magnesium combination tablets
|
|
Drug price
|
20.90 yen per tablet
Announced May 31, 2013
|
|
Indications and usage
|
Treatment and prevention of hypocalcemia associated with administration of RANKL inhibitors (genetically engineered denosumab)
|
|
Dosage and administration
|
Two tablets to be administered orally every day under normal circumstances. Dosage to be increased or decreased based on condition of the patient and clinical test results.
|
|
Approval date for manufacturing and marketing
|
February 28, 2013
|
|
Manufacturing and marketing
|
Nitto Pharmaceutical Industries, Ltd.
|
|
Marketing
|
Daiichi Sankyo Co., Ltd.
|